Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVAC vCP1452 and IL-2 in HIV Patients Undergoing HAART Interruption
NCT00056797Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2002
- Primary completion
- Mar 2006
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of ALVAC-HIV vCP1452, aldesleukin in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2002; status: completed.
02
Drugs
ALVAC-HIV vCP1452aldesleukin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00056797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056797.